Skip to contentE
Endovia Health Sciences, Inc.
E
EDVAEndovia Health Sciences, Inc. Q1 2020 · 10-Q
Revenue$112.00K$112.00K+4,102.7% vs Q1 2019 Net Income-$3.45M-$3.45MN/M vs Q1 2019 EPS Diluted-$0.05-$0.05N/M vs Q1 2019 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Endovia Health Sciences, Inc. · CIK 1553788 · Engraved from SEC EDGAR
Operating Cash Flow-$924,860N/M Free Cash Flowderived-$927,279N/M Margins · derivedGross margin4.3%+395.9 pt vs Q1 2019
Operating margin-1383.1%+15445.4 pt vs Q1 2019
Net margin-3077.3%+23325.1 pt vs Q1 2019
ended Mar 31, 2020 · filed May 13, 2020 · 43 d after period end